Latest Breaking News On - Philip toleikis - Page 1 : comparemela.com

SVA stock is undervalued, Research Capital says

A management shuffle at Sernova Corp isn’t dampening analyst Andre Uddin’s enthusiasm for the stock..

Brett whalenCynthia pussinenAndre uddinPhilip toleikisIpsen biosciencesIpsen biomeasureSpark therapeutics incSernova corp stockRoche groupTechnology officerSernova corpSernova corp stock quoteChief technologyChief executive officerChief technology officerChief technical officer

Sernova Corp Announces Executive Changes

Sernova Corp. announced that its Board of Directors has appointed Cynthia Pussinen as member of the Board of Directors. Dr. Philip Toleikis, who has led the company since 2009 as President and CEO.

United kingdomUnited statesPhilip toleikisCynthia pussinenIpsen biomeasureIpsen biosciencesRoche groupTechnical developmentUniversity of connecticutSpecialty chemicals for honeywell internationalRensselaer polytechnic instituteSpark therapeutics incSernova corpEuropean unionOperations supply chain for actinium pharmaceuticals incTechnology officer

2023-07-26 | TSX:SVA | Press Release

(2023-07-26 | TSX:SVA) Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph.D., MBA, as Chief Business Officer

United statesBritish columbiaUniversity of chicagoUnited kingdomCity ofPhilip toleikisSernova closecurlyquoteModestus obochiBusiness developmentSernova corpUniversity of british columbiaBaxter internationalUniversity of miamiPhlow corpChief business officerChief executive officer

Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph D , MBA, as Chief Business Officer

Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph D , MBA, as Chief Business Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

University of chicagoUnited statesUnited kingdomCity ofBritish columbiaModestus obochiCorey davisPhilip toleikisUniversity of british columbiaHannah holmquistlifesci communications telBaxter internationalPhd lifesci advisorsBusiness developmentInvestor relations sernova corpSernova corpPhlow corp

After First Approval, Experts Point to Barriers in Cell Therapy for Type 1 Diabetes

The FDA recently approved the first cellular therapy for Type 1 diabetes and others may not be far behind. But experts say challenges still exist to the widespread application of these treatments.

City ofUnited kingdomUnited statesCelltran lantidraDenise faustmanEli lillyPhilip toleikisMichael lehmickeAlliance for regenerative medicineHarvard medical schoolAmerican diabetes associationSigilon therapeuticsMassachusetts general hospitalRegenerative medicineInvestigational new drugCell pouch system